# Kristian Helin

Source: https://onco.cc/people/kristian-helin/  
OnCo record `kristian-helin` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Epigenetics researcher who leads the ICR, the academic institution with the most cancer drug discoveries.

## Summary

Kristian Helin is Chief Executive of The Institute of Cancer Research in London, the academic institution with the most cancer drug discoveries. His specialisms are epigenetics, chromatin and transcription, and institute leadership. He became Chief Executive in 2021 after leading the cell biology programme at Memorial Sloan Kettering and the Biotech Research and Innovation Centre in Copenhagen. His research concerns polycomb complexes, histone demethylases and epigenetic drug targets such as EZH2, and his PLoS Biology paper showed that the polycomb group protein EZH2 is required for mammalian circadian clock function. His ICR profile and PubMed listing are linked.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Chief Executive, The Institute of Cancer Research
- Specialisms: Epigenetics; Chromatin and transcription; Institute leadership

## Sources

- ICR: https://www.icr.ac.uk/
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Helin%20K%5BAuthor%5D%20epigenetic

## Connected records

- technologies: [Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)](https://onco.cc/technologies/epigenetic-drugs/)
- targets: [EZH2](https://onco.cc/targets/ezh2/)
- institutions: [The Institute of Cancer Research](https://onco.cc/institutions/icr-london/)

---
JSON: https://onco.cc/api/v1/entities/kristian-helin.json